- |||||||||| Ingrezza (valbenazine) / Neurocrine, Mitsubishi Tanabe, Austedo (deutetrabenazine) / Teva
Pharmacokinetic and Pharmacologic Characterization of the Dihydrotetrabenazine Isomers of Valbenazine and Deutetrabenazine (Grand Saguaro) - Oct 31, 2022 - Abstract #ACNP2022ACNP_890; Deutetrabenazine is metabolized to 4 deuHTBZ stereoisomers, the most abundant of which ([-]-α-deuHTBZ) has negligible interaction with VMAT2 in vitro and appreciable affinity for several off-target receptors- these findings were similar to what has been reported for tetrabenazine. Based on relative potency and abundance, [+]-β-deuHTBZ appears to be the primary contributor to VMAT2 inhibition of deutetrabenazine.
- |||||||||| (+)-α-dihydrotetrabenazine (ADE 513) / Adeptio Pharma, Ingrezza (valbenazine) / Neurocrine, Mitsubishi Tanabe, Austedo (deutetrabenazine) / Teva
Relationship Between Interleukin-6 (IL-6) Blood Levels and Treatment Outcome in Patients With Treatment-Resistant Bipolar Disorder Depression (TRBDD) (Grand Saguaro) - Oct 31, 2022 - Abstract #ACNP2022ACNP_308; Deutetrabenazine is metabolized to 4 deuHTBZ stereoisomers, the most abundant of which ([-]-α-deuHTBZ) has negligible interaction with VMAT2 in vitro and appreciable affinity for several off-target receptors- these findings were similar to what has been reported for tetrabenazine. Based on relative potency and abundance, [+]-β-deuHTBZ appears to be the primary contributor to VMAT2 inhibition of deutetrabenazine.
- |||||||||| (+)-?-dihydrotetrabenazine (ADE 513) / Adeptio Pharma
Trial completion: (+)-Alpha-Dihydrotetrabenazine Phase I (clinicaltrials.gov) - Aug 22, 2017 P1, N=6, Completed, Based on relative potency and abundance, [+]-β-deuHTBZ appears to be the primary contributor to VMAT2 inhibition of deutetrabenazine. Recruiting --> Completed
- |||||||||| (+)-?-dihydrotetrabenazine (ADE 513) / Adeptio Pharma
Trial primary completion date: (+)-Alpha-Dihydrotetrabenazine Phase I (clinicaltrials.gov) - Mar 28, 2017 P1, N=6, Recruiting, Recruiting --> Completed Trial primary completion date: Dec 2016 --> Jul 2017
- |||||||||| (+)-?-dihydrotetrabenazine (ADE 513) / Adeptio Pharma
Enrollment open: (+)-Alpha-Dihydrotetrabenazine Phase I (clinicaltrials.gov) - Aug 24, 2016 P1, N=6, Recruiting, Trial primary completion date: Dec 2016 --> Jul 2017 Not yet recruiting --> Recruiting
|